KEYTRUDA® (pembrolizumab) - Official Site
WEBLearn about KEYTRUDA® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. Visit the patient website.
Keytruda: 7 things you should know - Drugs.com
WEBJun 18, 2024 · Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including lung cancer, melanoma (a type of skin cancer), adenocarcinomas, endometrial carcinoma, and triple-negative breast cancer.
KEYTRUDA® (pembrolizumab) and LENVIMA® (lenvatinib) - Official Patient …
WEBPlease read the accompanying Patient Information for LENVIMA and discuss it with your doctor. The physician Prescribing Information also is available. Learn about how KEYTRUDA® (pembrolizumab) and LENVIMA® (lenvatinib) are used as a combination treatment for certain types of cancer.
Keytruda: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBSep 9, 2024 · Keytruda (pembrolizumab) is an immunotherapy medication that may be used to treat at least 18 different types of cancer such as melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), classical Hodgkin Lymphoma, endometri.
WEBPembrolizumab. This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider.
pembrolizumab (KEYTRUDA) | FDA - U.S. Food and Drug …
WEBOn August 5, 2016, the U. S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp.) for the treatment of patients with...
WEBKEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work.
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients …
WEBJul 27, 2021 · The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including …
KEYTRUDA® (pembrolizumab) | Indications and Efficacy Data for …
WEBKEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Frequently Asked Questions About Keytruda® (pembrolizumab)
WEBDec 19, 2018 · Keytruda is anti-PD-1 antibody. It blocks PD-1, a protein that interferes with certain types of immune responses and may enhance the ability of the immune system to fight cancer. How is Keytruda typically given (administered)? Keytruda is given by intravenous infusion, usually once every three weeks. Each infusion takes 30 minutes.